Log In
Print
BCIQ
Print
Print this Print this
 

MM-302

  Manage Alerts
Collapse Summary General Information
Company Merrimack Pharmaceuticals Inc.
DescriptionPegylated liposomal doxorubicin formulation targeting HER2
Molecular Target Epidermal growth factor receptor 2 (EGFR2) (HER2) (ErbB2) (neu)
Mechanism of ActionAntibody
Latest Stage of DevelopmentPhase I
IndicationBreast cancer
Partner

 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today